References
- Nutt D. Why medical cannabis is still out of patients’ reach—an essay by David Nutt. BMJ. 2019;365:l1903. doi: 10.1136/bmj.l1903
- Schlag AK. An evaluation of regulatory regimes of medical Cannabis: what lessons can Be learned for the UK? Med Cannabis Cannabinoids. 2020;3(1):76–83. doi: 10.1159/000505028
- Black N, Stockings E, Campbell G, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(12):995–1010. doi: 10.1016/S2215-0366(19)30401-8
- Stockings E, Campbell G, Hall WD, et al. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain. 2018;159(10):1932–1954. doi: 10.1097/j.pain.0000000000001293
- Lynskey MT, Schlag AK, Athanasiou-Fragkouli A, et al. Characteristics of and 3-month health outcomes for people seeking treatment with prescribed cannabis: real-world evidence from project Twenty21. Drug Sci Policy Law. 2023;9:20503245231167373.
- Arkell TR, Downey LA, Hayley AC, et al. Assessment of medical cannabis and health-related quality of life. JAMA Netw Open. 2023;6(5):e2312522. doi: 10.1001/jamanetworkopen.2023.12522
- Harris M, Erridge S, Ergisi M, et al. UK medical cannabis registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions. Expert Rev Clin Pharmacol. 2022;15(4):473–485. doi: 10.1080/17512433.2022.2017771
- Vigano A, Moride Y, Hachem Y, et al. The Quebec cannabis registry: investigating the safety and effectiveness of medical cannabis. Cannabis Cannabinoid Res. 2023;8(6):1106–1116. doi: 10.1089/can.2022.0041
- Schlag AK, Zafar RR, Lynskey MT, et al. The value of real world evidence: the case of medical cannabis. Front Psychiatry. 2022;13:1027159. doi: 10.3389/fpsyt.2022.1027159
- Bothwell LE, Podolsky SH. The emergence of the randomized, controlled trial. N Engl J Med. 2016;375(6):501–504. doi: 10.1056/NEJMp1604635
- Meldrum ML. A brief history of the randomized controlled trial. From oranges and lemons to the gold standard. Hematol Oncol Clin North Am. 2000;14(4):745–760. vii. doi: 10.1016/S0889-8588(05)70309-9
- He J, Morales DR, Guthrie B. Exclusion rates in randomized controlled trials of treatments for physical conditions: a systematic review. Trials. 2020;21(1):228. doi: 10.1186/s13063-020-4139-0
- Sakal C, Lynskey M, Schlag AK, et al. Developing a real-world evidence base for prescribed cannabis in the United Kingdom: preliminary findings from project Twenty21. Psychopharmacol (Berl). 2022;239(5):1147–1155. doi: 10.1007/s00213-021-05855-2
- Yang KH, Kaufmann CN, Nafsu R, et al. Cannabis: an emerging treatment for common symptoms in older adults. J Am Geriatr Soc. 2021;69(1):91–97. doi: 10.1111/jgs.16833
- Lynskey MT, Athanasiou-Fragkouli A, Thurgur A, et al. Medicinal cannabis for treating PTSD and comorbid depression: real world evidence from project Twenty21. 2023. [in press].
- Atakan Z. Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol. 2012;2(6):241–254. doi: 10.1177/2045125312457586